Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis

Takafumi Toyohara, Filip Roudnicky, Mary H.C. Florido, Toshiaki Nakano, Haojie Yu, Shunsuke Katsuki, Minjin Lee, Torsten Meissner, Max Friesen, Lance S. Davidow, Leon Ptaszek, Takaaki Abe, Lee L. Rubin, Alexandre C. Pereira, Masanori Aikawa, Chad A. Cowan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Why some patients with type 2 diabetes are protected against cardiovascular disease (CVD) has not been clarified. Toyohara et al. reveal that in patients protected from CVD, arylacetamide deacetylase (AADAC) is elevated in vascular smooth muscle cells (VSMCs). AADAC alters lipid metabolism and cellular processes in VSMCs and ameliorates CVD.

Original languageEnglish
Pages (from-to)147-157.e7
JournalCell stem cell
Volume27
Issue number1
DOIs
Publication statusPublished - Jul 2 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint Dive into the research topics of 'Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis'. Together they form a unique fingerprint.

  • Cite this

    Toyohara, T., Roudnicky, F., Florido, M. H. C., Nakano, T., Yu, H., Katsuki, S., Lee, M., Meissner, T., Friesen, M., Davidow, L. S., Ptaszek, L., Abe, T., Rubin, L. L., Pereira, A. C., Aikawa, M., & Cowan, C. A. (2020). Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis. Cell stem cell, 27(1), 147-157.e7. https://doi.org/10.1016/j.stem.2020.04.018